Bristol-Myers Squibb has completed a major expansion at its Devens, MA biologics facility designed to accelerate development of the company’s biologics portfolio     The $280 million investment adds new capabilities with a biologics development building for designing processes for the early production of investigational medicines, and a clinical manufacturing building to produce products to support clinical trials. The Devens site had previously focused solely on large-scale, bulk biologics ma...